• 43% increase in revenue to $36.8 million
• Adjusted EBITDA of $2.9 million, up from negative $1.6 million
• Profit after tax of $3.3 million, up 141% from prior year

Little Green Pharma Ltd has reported a strong financial performance for the year ended 31 March 2025, with revenue increasing 42.8% to $36.8 million and profit after tax up 140.8% to $3.3 million. The company's Adjusted EBITDA also improved significantly, moving from a negative $1.6 million in the prior year to a positive $2.9 million. The results were driven by continued growth in the Australian medicinal cannabis market as well as transformative regulatory changes in Europe, notably the partial legalisation of cannabis in Germany and the formalisation of the medicinal cannabis framework in France. LGP's strategy of vertical integration and one-stop-shop supply has enabled the company to deliver high-quality products efficiently and at scale. The acquisition of HHI (Australia) Pty Ltd during the year has also added depth to LGP's distribution capability and supported margin expansion. Looking ahead, LGP is well-positioned to capitalise on the consolidation expected in the medicinal cannabis sector, with its dual market leadership in Australia and Europe, significant Net Tangible Asset base, and substantial growing capacity in Denmark.

LGP expects to continue its strong growth trajectory, with revenue and profit expected to increase further in the 2026 financial year. The company's substantial growing capacity in Denmark and robust balance sheet, including a strong Net Tangible Asset position, provide a solid foundation for future expansion.

LGP is well-positioned to navigate the consolidation expected in the medicinal cannabis sector, with its dual market leadership in Australia and Europe, significant Net Tangible Asset base, and substantial growing capacity in Denmark. The company remains focused on its core values of Leadership, Imagination, and Trust, which have guided its success and will continue to underpin its strategy going forward.